Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Trial details
- Registry ID
- NCT06625320
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)NCT06625320 | RVMD | Phase 3 | Active not recruiting | 2026-06Estimated |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCNCT06162221 | RVMD | Phase 1, Phase 2 | Recruiting | 2027-06Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |